Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Earnings for Day One Biopharmaceuticals, Inc. (DAWN)
Earnings in 2023 (TTM): $-188,917,000
According to Day One Biopharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-188,917,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Day One Biopharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-188,917,000 | $-188,917,000 |
| 2022 | $-142,181,000 | $-132,176,000 |
| 2021 | $-72,754,000 | $-70,442,000 |
| 2020 | $-43,843,000 | $-40,506,000 |
| 2019 | $-16,984,000 | $-14,711,000 |